Longitudinal stability of CSF Tau levels in Alzheimer patients

Biological Psychiatry

Volumn 46, Issue 6, 1999, Pages 750-755

  Sunderland, Trey ^a   Wolozin, Benjamin ^a   Galasko, Douglas ^b   Levy, James ^a   Dukoff, Ruth ^a   Bahro, Marcel ^a   Lasser, Robert ^a   Motter, Ruth ^d   Lehtimäki, Terho ^c   Seubert, Peter ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d Athena Neurosciences Inc   (United States)

Author keywords

Cerebrospinal fluid; Dementia; Surrogate marker; Tau

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 0032821266     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00143-2     Document Type: Article

References (46)

1. Diagnostic and Statistical Manual of Mental Disorders. Third Edition, Revised. 1987;American Psychiatric Association, Washington.
2. Andreasen N., Vanmechelen E., Van de Voorde A. Cerebrospinal fluid tau protein as a marker for Alzheimer's disease A community based follow up study . J Neurol Neurosurg Psychiatry. 64:1998;298-305.
3. Arai H., Higuchi S., Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein Implications for the clinical diagnosis of Alzheimer's disease . Gerontology. 43:(suppl 1):1997;2-10.
4. Arai H., Terajima M., Miura M., et al. Tau in cerebrospinal fluid a potential diagnostic marker in Alzheimer's disease . Ann Neurol. 38:1995;649-652.
5. Baumann K., Mandelkow E.-M., Biernat J., et al. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336:1993;417-424.
6. Blomberg M., Jensen M., Basun H., et al. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele E4 during 14 months follow-up. Neurosci Lett. 214:1996;163-166.
7. DeKosky S.T., Harbaugh R.E., Schmitt F.A., et al. Cortical biopsy in Alzheimer's disease Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations . Ann Neurol. 32:1992;625-632.
8. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician . J Psychiatry Res. 12:1975;189-198.
9. Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid Beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 55:1998;937-945.
10. Galasko D., Clark C., Chang L., et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48:1997;632-635.
11. Galasko D., Hansen L., Vigo-Pelfrey C., et al. Antemortem CSF Tau is related to neuronal pathology at autopsy in Alzheimer's disease. Soc Neurosci Abstr. 21:1995;581.
12. Ghanbari H.A., Miller B.E., Haigler H.J., et al. Biochemical assay of Alzheimer's disease - associated protein(s) in human brain tissue. A clinical study. JAMA. 263:1990;2907-2910.
13. Goedert M., Jakes R., Spillantini M.G., et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature. 383:1996;550-553.
14. Golombowski S., Muller-Spahn F., Romig H., et al. Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett. 225:1997;213-215.
15. Hock C., Golombowski S., Naser W., et al. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol. 37:1995;414-415.
16. Hughes C.P., Berg L., Danziger W.L., et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 140:1982;566-572.
17. Jensen M., Basun H., Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 186:1995;189-191.
18. Johnson G.V.W., Seubert P., Cox T.M., et al. The τ protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments. Int J Neurochem. 68:1998;430-433.
19. Kanai M., Matsubara E., Isoe K., et al. Longitudinal study of cerebrospinal fluid levels of tau, abeta1-40, and abeta1-42(3) in Alzheimer's disease A study in Japan . Ann Neurol. 44:1998;17-26.
20. Khatoon S., Grundke-Iqbal I., Iqbal K. Brain levels of microtubule-associated protein τ are elevated in Alzheimer's disease A radioimmuno-slot-blot assay for nanograms of the protein . J Neurochem. 59:1992;750-753.
21. Lehtimäki T., Moilanen T., Viikari J., et al. Apolipoprotein E phenotypes in Finnish youths a cross-sectional and 6-year follow-up study . J Lipid Res. 31:1990;487-495.
22. Lehtimäki T., Pirttila T., Mehta P.D., et al. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet. 95:1995;39-42.
23. Mandelkow E.-M., Mandelkow E. Tau as a marker for Alzheimer's disease. Trends Biochem Sci. 18:1993;480-483.
24. McKeith I.G., Galasko D., Kosaka K., et al. Consensus guidelines international workshop for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB) Report of the consortium on DLB . Neurology. 47:1996;1113-1124.
25. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease . Neurology. 34:1984;939-944.
26. Mendez M.F., Mastri A.R., Sung J.H., et al. Clinically diagnosed Alzheimer disease Neuropathologic findings in 650 cases . Alzheimer Dis Assoc Disord. 6:1992;35-43.
27. Menzel H.-J., Utermann G. Apolipoprotein E phenotyping from serum by Western blotting. Electrophoresis. 7:1986;492-495.
28. Mori H., Hosoda K., Matsubara E., et al. Tau in cerebrospinal fluids Establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau . Neurosci Lett. 186:1995;181-183.
29. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 38:1995;643-648.
30. Munroe W.A., Southwick P.C., Chang L., et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 25:1995;207-217.
31. Parnetti L., Palumbo B., Cardinali L., et al. Cerebrospinal fluid neuron-specific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett. 183:1995;43-45.
32. Pizzi M., Valerio A., Arrighi V., et al. Antisense strategy unravels tau proteins as molecular risk factors for glutamate-induced neurodegeneration. Cell Mol Neurobiol. 14:1994;569-578.
33. Pizzi M., Valerio A., Arrighi V., et al. Inhibition of glutamate-induced neurotoxicity by a tau antisense oligonucleotide in primary culture of rat cerebellar granule cells. Eur J Neurosci. 7:1995;1603-1613.
34. Reisberg B., Ferris S.H., DeLeon M.J., et al. The Global Deterioration Scale for Assessment of Primary Degenerative Dementia. Am J Psychiatry. 139:1982;1136-1139.
35. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 212:1996;209-211.
36. Samuel W., Terry R.D., Maslich E. Frontal cortex and nucleus basalis pathology in Alzheimer's disease. Arch Neurol. 51:1994;772-778.
37. Skoog I., Vanmechelen E., Andreasson L.A., et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds Relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein allele E4 during 14 months follow-up . Neurosci Lett. 214:1996;163-166.
38. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease . Proc Natl Acad Sci USA. 90:1993;1977-1981.
39. Tapiola T., Overmyer M., Lehtovirta M., et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport. 8:1997;3961-3963.
40. Tato R.E., Frank A., Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 59:1995;280-283.
41. Terry R.D. Neuropathological changes in Alzheimer disease. Svennerholm L., Asbury A.K., Reisfeld R.A., et al. Progress in Brain Research. 1994;303-390 Elsevier, Amsterdam.
42. Terry R.D., Hansen L.A., DeTeresa R., et al. Senile dementia of the Alzheimer type without neocortical neurofibrillarly tangles. J Neuropathol Exp Neurol. 46:1987;2262-2268.
43. Vandermeeren M., Mercken M., Vanmechelen E., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 61:1993;1828-1834.
44. Victoroff J., Mack W.J., Lyness S.A., et al. Multicenter clinicopathological correlation in dementia. Am J Psychiatry. 152:1995;1476-1484.
45. Vigo-Pelfrey C., Seubert P., Barbour R., et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 45:1995;788-793.
46. Wolozin B., Davies P. Alzheimer-related neuronal protein A68 Specificity and distribution . Ann Neurol. 22:1987;521-526.